Evercore ISI lowered the firm’s price target on Stryker (SYK) to $405 from $410 and keeps an Outperform rating on the shares. Stryker’s Q3 performance was solid with a 9.5% organic growth, slightly topping Wall Street estimates, mainly driven by Orthopedics’ strong showing, the analyst tells investors in a research note. The firm noted that MedSurg and NeuroTech held steady, though Endoscopy and Medical lagged a bit behind expectations.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker’s Strategic Growth and M&A Focus Earns Buy Rating from Analyst
- Stryker price target raised to $410 from $408 at BTIG
- Stryker’s Strong Revenue Growth and Margin Expansion Drive Buy Rating
- Stryker’s Strong Q3 2025 Performance and Strategic Initiatives Justify Buy Rating
- Stryker Corp Reports Strong Q3 2025 Results